vida: extract claims from 2026-05-08-exenatide-parkinsons-phase3-lancet-failure

- Source: inbox/queue/2026-05-08-exenatide-parkinsons-phase3-lancet-failure.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md

@@ -10,15 +10,17 @@ agent: vida
 sourced_from: health/2026-05-07-lancet-evoke-semaglutide-alzheimers-failure.md
 scope: correlational
 sourcer: EVOKE trial investigators
-supports:
-- Semaglutide fails to slow Alzheimer's disease progression despite biomarker effects distinguishing metabolic risk reduction from disease-modifying potential in established neurodegeneration
-related:
-- GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways
-reweave_edges:
-- GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways|related|2026-05-08
-- Semaglutide fails to slow Alzheimer's disease progression despite biomarker effects distinguishing metabolic risk reduction from disease-modifying potential in established neurodegeneration|supports|2026-05-08
+supports: ["Semaglutide fails to slow Alzheimer's disease progression despite biomarker effects distinguishing metabolic risk reduction from disease-modifying potential in established neurodegeneration"]
+related: ["GLP-1 receptor agonists demonstrate circuit-specific CNS effects\u2014efficacy in reward pathways but not neurodegenerative pathways", "glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials", "semaglutide-fails-alzheimers-progression-despite-biomarker-effects-distinguishing-metabolic-prevention-from-neurodegeneration-treatment", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure"]
+reweave_edges: ["GLP-1 receptor agonists demonstrate circuit-specific CNS effects\u2014efficacy in reward pathways but not neurodegenerative pathways|related|2026-05-08", "Semaglutide fails to slow Alzheimer's disease progression despite biomarker effects distinguishing metabolic risk reduction from disease-modifying potential in established neurodegeneration|supports|2026-05-08"]
 ---
 
 # GLP-1 biomarker improvement without clinical benefit demonstrates surrogate endpoint limitation in neurodegeneration trials
 
-The EVOKE trials produced a striking disconnection: statistically significant 10% reduction in CSF p-tau181 at week 78, yet zero change in Clinical Dementia Rating Sum of Boxes (CDR-SB) or Activities of Daily Living (ADCS-ADL-MCI) at week 104. Trial experts agreed the biomarker magnitude was insufficient to provide patient benefit. This pattern—positive biomarker, negative clinical outcome—is mechanistically informative for understanding surrogate endpoints in neurodegeneration. It suggests GLP-1 is producing a measurable molecular effect (likely anti-inflammatory given the p-tau181 target), but that effect is either: (1) too small to overcome established pathology, (2) targeting a pathway that is not rate-limiting for disease progression, or (3) measuring a consequence rather than a cause of neurodegeneration. The finding has regulatory implications for FDA's accelerated approval pathway based on biomarker surrogates: a drug can move a biomarker in the 'right' direction without producing clinical benefit. This is particularly relevant given recent controversies around amyloid-targeting therapies approved on biomarker endpoints. The EVOKE result demonstrates that p-tau181 reduction, at least at the 10% magnitude achieved by semaglutide, is not a validated surrogate for clinical benefit in Alzheimer's disease.
+The EVOKE trials produced a striking disconnection: statistically significant 10% reduction in CSF p-tau181 at week 78, yet zero change in Clinical Dementia Rating Sum of Boxes (CDR-SB) or Activities of Daily Living (ADCS-ADL-MCI) at week 104. Trial experts agreed the biomarker magnitude was insufficient to provide patient benefit. This pattern—positive biomarker, negative clinical outcome—is mechanistically informative for understanding surrogate endpoints in neurodegeneration. It suggests GLP-1 is producing a measurable molecular effect (likely anti-inflammatory given the p-tau181 target), but that effect is either: (1) too small to overcome established pathology, (2) targeting a pathway that is not rate-limiting for disease progression, or (3) measuring a consequence rather than a cause of neurodegeneration. The finding has regulatory implications for FDA's accelerated approval pathway based on biomarker surrogates: a drug can move a biomarker in the 'right' direction without producing clinical benefit. This is particularly relevant given recent controversies around amyloid-targeting therapies approved on biomarker endpoints. The EVOKE result demonstrates that p-tau181 reduction, at least at the 10% magnitude achieved by semaglutide, is not a validated surrogate for clinical benefit in Alzheimer's disease.
+
+## Supporting Evidence
+
+**Source:** Exenatide-PD3 Phase 3 RCT, Lancet February 2025
+
+Exenatide Phase 3 showed no DaT-SPECT signal change versus placebo, meaning the biomarker tracking dopaminergic neuron degeneration showed zero neuroprotection. This directly confirms that biomarker improvement (or lack thereof) can fail to translate to clinical benefit in neurodegeneration trials. The Phase 2 motor benefit (P=0.001) did not replicate in Phase 3, suggesting the earlier biomarker signal was spurious or underpowered.

domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md

@@ -11,9 +11,16 @@ sourced_from: health/2026-05-07-glp1-cns-circuit-specificity-synthesis.md
 scope: causal
 sourcer: Vida synthesis
 supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
-related: ["medical-care-explains-only-10-20-percent-of-health-outcomes", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence"]
+related: ["medical-care-explains-only-10-20-percent-of-health-outcomes", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure", "glp1-cns-effects-circuit-specific-reward-not-neurodegenerative"]
 ---
 
 # GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration
 
 Converging evidence from multiple 2025-2026 trials reveals a clear anatomical pattern in GLP-1 CNS efficacy. WHERE GLP-1 WORKS: Substance use disorders show 68-75% lower odds across alcohol, opioid, nicotine, and cannabis use (All of Us observational, n>1M). Alcohol use disorder RCT demonstrated 41% reduction in heavy drinking days with NNT 4.3. Depression/anxiety/SUD worsening in pre-existing mental illness reduced 42% (Lancet Psychiatry within-individual design). MDD motivation/avolition improved in April 2026 RCT. Parkinson's motor function showed preliminary improvement across 5 Phase 2 studies. WHERE GLP-1 FAILS: Alzheimer's disease progression showed NO clinical benefit in EVOKE + EVOKE+ trials (n=3,800, Lancet March 2026) despite 10% p-tau181 biomarker reduction. No secondary endpoint improvement in any cognitive or functional domain. MECHANISTIC EXPLANATION: GLP-1 receptors concentrate in VTA, nucleus accumbens, insula, and prefrontal cortex—the reward/motivation circuits dysregulated in SUD, MDD avolition, and Parkinson's motor control (substantia nigra dopaminergic degeneration). These are NOT the circuits disrupted in Alzheimer's (medial temporal lobe, hippocampus, amyloid/tau cascade). The biomarker improvement in EVOKE likely reflects anti-inflammatory effects—real but insufficient to modify established neurodegeneration. IMPLICATION: Observational evidence showing GLP-1 users have lower dementia incidence probably reflects metabolic risk reduction (obesity, T2D → reduced vascular dementia risk) rather than direct neuroprotection. Remove the metabolic confound (EVOKE enrolled non-metabolic confirmed AD patients) and the effect disappears. This circuit specificity explains why GLP-1 crosses the clinical/non-clinical boundary specifically at the reward/behavioral interface—not generally across all CNS conditions.
+
+
+## Supporting Evidence
+
+**Source:** Exenatide-PD3 Phase 3 RCT, Lancet February 2025
+
+Exenatide Phase 3 trial (n=194, 96 weeks) failed all endpoints in Parkinson's disease: no motor benefit, no non-motor benefit, and critically, DaT-SPECT imaging showed zero dopaminergic neuroprotection signal. CSF analysis revealed insufficient drug penetration to substantia nigra despite exenatide crossing the BBB in other brain regions. This confirms the circuit-specificity principle: GLP-1 agonists succeed in reward/dopamine circuits (SUD, MDD) but fail in neurodegenerative contexts where the mechanism is protein aggregation (α-synuclein) rather than reward dysregulation.

entities/health/exenatide-pd3-trial.md

@@ -0,0 +1,56 @@
+---
+type: entity
+entity_type: research_program
+name: Exenatide-PD3 Trial
+domain: health
+status: completed
+---
+
+# Exenatide-PD3 Trial
+
+**Type:** Phase 3 randomized controlled trial  
+**Drug:** Exenatide (GLP-1 receptor agonist)  
+**Indication:** Parkinson's disease (disease-modifying therapy)  
+**Design:** Multicenter, double-blind, placebo-controlled, n=194, 96 weeks  
+**Sites:** 6 UK research hospitals  
+**Funding:** National Institute for Health and Care Research (NIHR)  
+**Primary Endpoint:** Movement symptom progression (motor function)  
+**Status:** Failed (February 2025)
+
+## Overview
+
+Exenatide-PD3 was the largest and longest GLP-1 receptor agonist trial in Parkinson's disease to date. It tested whether exenatide once-weekly could slow disease progression by providing neuroprotection to dopaminergic neurons in the substantia nigra.
+
+## Results
+
+**Primary endpoint:** FAILED — exenatide did not stop movement symptoms from worsening over 96 weeks versus placebo.
+
+**Secondary endpoints:** FAILED — no benefit in non-motor symptoms (quality of life, cognition, mood) compared to placebo.
+
+**DaT-SPECT imaging:** No significant change versus placebo. This biomarker tracks dopaminergic neuron degeneration; zero signal indicates no neuroprotection at the structural level.
+
+**CSF analysis (mechanistic finding):** Only small amounts of exenatide reached the substantia nigra, the brain region affected by Parkinson's. This suggests insufficient CNS penetration to the target region, despite exenatide crossing the blood-brain barrier in other areas.
+
+## Context
+
+This trial directly contradicts earlier Phase 2 work (Foltynie group, n=59) which showed significant motor benefit at 9 months (P=0.001). The Phase 3 failure raises questions about:
+- Phase 2 selection bias or underpowering
+- Regional brain penetrance as the limiting factor (not BBB crossing per se)
+- Whether the Phase 2 signal was spurious
+
+## Implications
+
+The failure complicates the GLP-1 neuroprotection hypothesis. Two other GLP-1 agonists (semaglutide, liraglutide) remain in ongoing Phase 3 trials for Parkinson's. The CSF finding suggests that different GLP-1 agonists with distinct CNS penetration mechanisms (e.g., semaglutide via albumin binding → tanycytes) may achieve different substantia nigra concentrations and potentially different outcomes.
+
+## Expert Response
+
+Dr. Katherine Fletcher (Parkinson's UK): "Really disappointing news" and "a setback." Concerns raised that the failure may impact funding for other GLP-1 trials in Parkinson's.
+
+## Timeline
+
+- **2025-02-04** — Phase 3 results published in The Lancet: all endpoints failed, CSF analysis reveals insufficient substantia nigra penetration
+
+## References
+
+- The Lancet, February 4, 2025: [Exenatide-PD3 Phase 3 Results](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02808-3/fulltext)
+- Parkinson's UK press response, February 2025

inbox/archive/health/2026-05-08-exenatide-parkinsons-phase3-lancet-failure.md

@@ -7,10 +7,13 @@ date: 2025-02-04
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-08
 priority: high
 tags: [GLP-1, Parkinson's disease, neurodegenerative disease, Phase 3 RCT, exenatide, CNS penetrance, drug failure]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content